SCHEMBL4071083

SCHEMBL4071083

Cc1cccc2cc(C=O)c(=O)[nH]c12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.61
DDO Q99489 1/20 0.61
KDM4E B2RXH2 10/20 0.49
HSD17B10 Q99714 3/20 0.49
ALDH1A1 P00352 7/20 0.48
HPGD P15428 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TRIM24 O15164 1/20 0.46
TRIM33 Q9UPN9 1/20 0.46
RXFP1 Q9HBX9 2/20 0.46
GLA P06280 1/20 0.46
KMT2A Q03164 1/20 0.44
GRIA1 P42261 1/20 0.42
GRIA2 P42262 1/20 0.42
GRIA3 P42263 1/20 0.42
GRIA4 P48058 1/20 0.42
ATM Q13315 2/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29956813 0.81 DAO (0.63) DAODDOKDM4EHSD17B10ALDH1A1
SCHEMBL12559601 0.80 DAO (0.71) DAODDOKDM4EHSD17B10ALDH1A1
SCHEMBL29951711 0.80 HSD17B10 (0.47) DAODDOKDM4EHSD17B10ALDH1A1
SCHEMBL4069728 0.80 DAO (0.61) DAODDO
SCHEMBL5449128 0.80 HSD17B10 (0.47) DAODDOKDM4EHSD17B10ALDH1A1
SCHEMBL29955653 0.80 DAO (0.61) DAODDOKDM4EALDH1A1NPSR1
SCHEMBL4200518 0.80 DAO (0.49) DAODDOKDM4EHSD17B10ALDH1A1
SCHEMBL29955346 0.80 ALDH1A1 (0.52) DAOKDM4EALDH1A1KMT2ALMNA
SCHEMBL4070484 0.79 HSD17B10 (0.52) DAODDOKDM4EHSD17B10ALDH1A1
SCHEMBL5366835 0.77 DAO (0.53) DAODDOKDM4EHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
WO-2008113006-A1 METHODS OF USING QUINOLINONE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-09-18 WO disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG DAO 705/4885DDO 348/4885KDM4E 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.